Walleye Capital
ALBO

Walleye Capital’s Albireo Pharma Inc ALBO Stock Holding History

Walleye Capital’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-38,178
Closed -$739K – 3825
2022
Q3 		$739K Buy
+38,178
New +$790K 0.01% 1176

Other funds holding ALBO

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Walleye Capital's ALBO Position: Q4 2022 in Review

Walleye Capital sold out of Albireo Pharma Inc (ALBO) in Q4 2022, closing a stake of 38,178 shares — an estimated $739K sold.

Walleye Capital first reported a position in ALBO in Q3 2022 and held it in 1 quarter. The position peaked at $739K in Q3 2022. 96 funds tracked by Wall St. Rank hold ALBO as of Q4 2022.

  • Walleye Capital reported no remaining Albireo Pharma Inc position as of Q4 2022 after selling out during the quarter.
  • Walleye Capital sold 38,178 Albireo Pharma Inc shares in Q4 2022, an estimated $739K.
  • Walleye Capital first reported a position in Albireo Pharma Inc in Q3 2022 and held it in 1 quarter.
  • Walleye Capital's Albireo Pharma Inc position peaked at $739K in Q3 2022.
  • 96 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2022.

Based on Walleye Capital's 13F filing for Q4 2022, filed 14 Feb 2023.